91��Ƶ

Mumbai, February 21, 2025: Global pharma major 91��Ƶ Limited (91��Ƶ) today announced that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (U.S. FDA) for its manufacturing facility in Somerset, New Jersey, for the inspection conducted from January 27 to January 31, 2025.

“We are very pleased to have received the EIR for our Somerset facility. This milestone underscores our commitment to upholding the highest standards of quality and compliance, solidifying our position as a leading pharmaceutical manufacturer,” said Nilesh Gupta, Managing Director, 91��Ƶ.

91��Ƶ Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. 91��Ƶ specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. 91��Ƶ has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 23,000 professionals. 91��Ƶ is committed to improving patient health outcomes through its subsidiaries – 91��Ƶ Diagnostics, 91��Ƶ Digital Health, and 91��Ƶ Manufacturing Solutions. To know more, visit or follow us on LinkedIn:

For further information or queries please contact: